| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 153.9MM | +14% |
| Gross Profit | 134.3MM | - |
| Cost Of Revenue | 19.6MM | -7% |
| Operating Income | 8.1MM | -146% |
| Operating Expenses | 126.1MM | - |
| Net Income | -16MM | - |
| R&D | 22.7MM | -7% |
| G&A | 82.7MM | -5% |
| Amortization | 21.2MM | +6% |
| Interest Expense | 0 | -100% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD). The FDA has issued a Complete Response Letter (CRL) in response to the company’s New Drug Application (NDA) for SPN-830. The CRL indicates that the review cycle for the application is complete but that the application still needs to be prepa
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD) under U.S. Food and Drug Administration (FDA) review. The FD
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Jefferies Biotech on the Bay SummitDate:Tuesday, March 12, 2024Place:The 1 Hotel South Beach, Miami, Fla. Barclays Glob
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in. If you want to skip our overview of the global pharmaceutical and healthcare industry, which is one the most unique sectors in the world, then you can check out 5 Best Small Cap Pharma Stocks to […]
Supernus Pharmaceuticals ( NASDAQ:SUPN ) Full Year 2023 Results Key Financial Results Revenue: US$607.5m (down 8.9...
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET at the Marriott Copley Place in Boston, Mass. Inves
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript February 27, 2024 Supernus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the Supernus Pharmaceuticals’ Fourth Quarter and Full Year 2023 Financial Results Conference […]
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Supernus (SUPN) delivered earnings and revenue surprises of -95.12% and 6.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?